David Ross, Senior Medical Director, Lung Transplantation and Molecular Diagnostics at Natera, shared on LinkedIn:
“Exciting new therapeutic options for Stage 4A NSCLC in DREAM!”
Quoting Natera:
“DREAMing beyond stage IVA: Lung transplantation and molecular surveillance
Join the Northwestern Lung Transplant team behind the groundbreaking DREAM Study as they share findings from its recent JAMA publication.
A new frontier: Transplant as a viable option for patients with primary lung stage IVA cancer-offering a path forward to those who previously had no alternatives. Balancing the risk of recurrence and rejection is complicated for these patients. Particularly because recurrence is a major concern with a 40-50% chance of recurrence after double lung transplant of stage IVA NSCLC.
Innovation that makes it possible: With the combined power of Signatera and Prospera, these patients benefit from molecular detection of recurrence with ongoing rejection surveillance to ensure the right balance of immunosuppression.
